Exemplar Genetics to Present on Novel Research Models for Oncology at the World Preclinical Congress
Sioux Center, IA, June 15, 2016 – Exemplar Genetics announced its President, John Swart, Ph.D., will present today at the 15th Annual World Preclinical Congress during the Preclinical Models in Oncology session.
Game-Changing Animal Research Models Offer Superior Translational Research and Better Predictive Efficacy
First Genetically Engineered Miniswine Research Model Cleared by FDA for Commercial Use
Dr. Swart to Present on Novel Preclinical Model in Oncology on June 15th at World PreClinical Congress.
June 15, 2016 at 4:05 Westin Boston Waterfront Boston, MA
Exemplar Genetics to Exhibit at BIO 2016
June 6-9, 2016 Booth 535
ExeGen LDLR MiniSwine
Features consistent, stable hypercholesterolemia that can be further modulated by diet. Predictable, progressive atherosclerosis that manifests on an accelerated timeline. Atherosclerotic lesion formation in the aorta and coronary arteries that model key pathophysiological aspects of human atherosclerosis. Defined Yucatan miniature swine genetics that offers greater consistency.
A rare opportunity arises for an family fighting a rare disease
“You could have picked me up off of the floor. Out of 50,000 people at a conference, the chances of meeting someone researching A-T is very, very rare. Dr. Swart never could have imagined that I was connected to the organization or a mother of three A-T adults. I told him that maybe I could help,” Amy said, laughing.
Discovery drives the human race to new heights each day.
Explorers in all fields have made our lives and world better through their courage to venture into new frontiers and beyond. Yet, their ability to discover has always relied on the proper vehicle to propel them from theory to reality. At Exemplar Genetics, we enable discovery by providing the vehicle to break new ground on the medical research frontier.
Until now, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics.